SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES

被引：0
|
作者：
Deodhar, A. [1 ]
Baraliakos, X. [2 ]
Marzo-Ortega, H. [3 ,4 ]
Sieper, J. [5 ]
Gupta, A. D. [6 ]
Porter, B. [7 ]
Fox, T. [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Ruhr Univ Bochum, Bochum, Germany
[3] Univ Leeds, Leeds Teaching Hosp Trust, Leeds, W Yorkshire, England
[4] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[5] Charite, Berlin, Germany
[6] Novartis Healthcare, Hyderabad, India
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
    Deodhar, Atul A.
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    Sieper, Joachim
    Andersson, Mats
    Porter, Brian
    Fox, Todd
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [2] SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 TRIALS
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Andersson, M.
    Porter, B.
    Fox, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 340 - 341
  • [3] SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE UP TO THREE YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE III TRIALS
    Barkham, Nick
    Deodhar, Atul
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    Sieper, Joachim
    Andersson, Mats
    Porters, Brian
    Fox, Todd
    RHEUMATOLOGY, 2018, 57
  • [4] SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE OVER LONG-TERM EXPOSURE (UP TO 4 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS - UPDATED POOLED ANALYSIS OF THREE PHASE 3 TRIALS
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Martin, R.
    Porter, B.
    Shete, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 727 - 727
  • [5] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Machado, Pedro M.
    Gensler, Lianne S.
    Marzo-Ortega, Helena
    Sherif, Bintu
    Quebe-Fehling, Erhard
    Porter, Brian
    Gaillez, Corine
    Deodhar, Atul
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 273 - 288
  • [6] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Xenofon Baraliakos
    Filip Van den Bosch
    Pedro M. Machado
    Lianne S. Gensler
    Helena Marzo-Ortega
    Bintu Sherif
    Erhard Quebe-Fehling
    Brian Porter
    Corine Gaillez
    Atul Deodhar
    Rheumatology and Therapy, 2021, 8 : 273 - 288
  • [7] SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES
    Deodhar, A.
    Mcinnes, I.
    Baraliakos, X.
    Reich, K.
    Gottlieb, A. B.
    Lebwohl, M.
    Schreiber, S.
    Bao, W.
    Marfo, K.
    Richards, H.
    Pricop, L.
    Shete, A.
    Safi, J.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 718 - 718
  • [8] SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES
    McInnes, Iain B.
    Baraliakos, Xenofon
    Deodhar, Atul
    Gottlieb, Alice B.
    Lebwohl, Mark
    Schreiber, Stefan
    Marfo, Kwaku
    Bao, Weibin
    Richards, Hanno B.
    Pricop, Luminita
    Shete, Abhijit
    Safi, Jorge
    Mease, Philip J.
    RHEUMATOLOGY, 2021, 60
  • [9] Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: Updated pooled safety analyses
    Gottlieb, Alice
    Deodhar, Atul
    McInnes, Iain B.
    Baraliakos, Xenofon
    Reich, Kristian
    Schreiber, Stefan
    Bao, Weibin
    Richards, Hanno B.
    Pricop, Luminita
    Mease, Philip J.
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB61 - AB61
  • [10] Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Deodhar, Atul A.
    Baeten, Dominique
    Sieper, Joachim
    Porter, Brian
    Widmer, Albert
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345